All In Biotech

Drug Trial Radar · NCT02722538

Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer

A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Muscle-Invasive Transitional Cell Carcinoma of the Bladder

Last checked: Nov 19, 2026Latest source record: Sep 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

23

Actual

Start

May 31, 2016

Primary completion

May 2, 2019

Study completion May 2, 2019

Sponsor

Lead sponsor
Taris Biomedical LLCIndustry
Sponsor type
Industry
First posted
Mar 30, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if TAR-200, an investigational drug-delivery system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) between diagnosis and radical cystectomy (RC).

Conditions

  • Urinary Bladder Cancer

Interventions

  • Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200Drug

    TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical drug delivery system, regulated as a drug, whose primary mode of action is the controlled release of gemcitabine into the bladder over a 7-day period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment emergent adverse events (TEAEs) coded with MedDRA and graded for severity with CTCAE v4.0Time frame: Maximum 132 days

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Southern California Norris Comprehensive Cancer Center

    Los Angeles, California

  • University of Chicago Medical Center

    Chicago, Illinois

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Columbia University Medical Center

    New York, New York

  • Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Radboudumc

    Nijmegen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.